E

Entera Bio Ltd

D
ENTX
USD
-0.06
(-2.8708%)
Market Closed
710.00
Volume
-0.23
EPS
-
Div Yield
-7.807692
P/E
73,738,895.37
Market Cap
Today
-2.8708%
1 Week
12.590%
1 Month
25.309%
6 Months
41.958%
12 Months
190.000%
Year To Date
238.333%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
AUPH
0.125
(1.768%)
USD
B
BIIB
3.82
(1.9334%)
USD
ABBV
ABBV
0.73
(0.3784%)
USD
GILD
GILD
0.015
(0.0179%)
USD
MRK
MRK
-1.44
(-1.2137%)
USD
REGN
REGN
11.33
(0.9948%)
USD
I
INCY
1.67
(2.5625%)
USD
AMGN
AMGN
3.02
(0.9071%)
USD
K
KPTI
-0.0002
(-0.027%)
USD

Title:
Entera Bio Ltd

Sector:
Healthcare
Industry:
Biotechnology
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Do you need help or have a question?
Contact Us